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Abstract
Urothelial carcinoma (UC) causes substantial morbidity and mortality worldwide. However, the molecular mechanisms underly-
ing urothelial cancer development and tumor progression are still largely unknown. Using informatics analysis, we identified
Sh3gl2 (endophilin A1) as a bladder urothelium–enriched transcript. The gene encoding Sh3gl2 is located on chromosome 9p,
a region frequently altered in UC. Sh3gl2 is known to regulate endocytosis of receptor tyrosine kinases implicated in onco-
genesis, such as the epidermal growth factor receptor (EGFR) and c-Met. However, its role in UC pathogenesis is unknown.
Informatics analysis of expression profiles as well as immunohistochemical staining of tissue microarrays revealed Sh3gl2
expression to be decreased in UC specimens compared to nontumor tissues. Loss of Sh3gl2 was associated with increasing
tumor grade and with muscle invasion, which is a reliable predictor of metastatic disease and cancer-derived mortality. Sh3gl2
expression was undetectable in 19 of 20 human UC cell lines but preserved in the low-grade cell line RT4. Stable silencing of
Sh3gl2 in RT4 cells by RNA interference 1) enhanced proliferation and colony formation in vitro, 2) inhibited EGF-induced EGFR
internalization and increased EGFR activation, 3) stimulated phosphorylation of Src family kinases and STAT3, and 4) promoted
growth of RT4 xenografts in subrenal capsule tissue recombination experiments. Conversely, forced re-expression of Sh3gl2 in
T24 cells and silenced RT4 clones attenuated oncogenic behaviors, including growth and migration. Together, these findings
identify loss of Sh3gl2 as a frequent event in UC development that promotes disease progression.
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Introduction
Current estimates indicate that more than 73,000 new cases of
urothelial carcinoma (UC) of the bladder and upper urinary tract are
diagnosed annually in the United States alone, with ∼15,000 deaths
from the disease predicted annually [1]. UC affects the kidney, ureter,
and bladder. UC has the highest rate of recurrence of any malignancy
and, as a consequence, is the most expensive of all solid tumors to
treat [2,3]. Despite this significant healthcare burden, the current stan-
dards of care for UC result in modest clinical benefit and infrequent
cure. Disease management is hampered by a lack of prognostic markers
capable of predicting the likely disease course and the potential for
response to a given therapeutic regimen. Thus, there is an urgent need
for identification and characterization of the molecular alterations that
underlie lethal disease and that identify more aggressive tumors early
for radical and/or novel therapies. Such findings would allow for trans-
lation of such knowledge into new clinical strategies.
A number of molecular changes have been associated with develop-
ment and progression of UC. These include 1) alterations in expres-
sion and regulation of the receptor tyrosine kinases (RTKs), fibroblast
growth factor receptor 3, and members of the epidermal growth fac-
tor receptor (EGFR/ERBB) family (reviewed in [4]); 2) up-regulation
of signaling through the RAS and phosphatidylinositol 3-kinase/AKT
pathways [5]; and 3) functional down-regulation of the tumor sup-
pressors, p53, pRb, and p16, through deletion, mutation, and/or
silencing. However, the extent to which these changes could be ex-
ploited for therapeutic benefit remains undefined. For example, ligand-
mediated activation of ERBB signaling promotes multiple activities
of relevance to tumorigenesis, such as cell survival, proliferation, migra-
tion, and invasion [6], suggesting that ERBB family members may be
effective therapeutic targets. In spite of this, clinical trials targeting the
EGFR and/or ERBB2 with tyrosine kinase inhibitors in unselected
patients have been unsuccessful to date [7–10]. Thus, additional factors
regulating RTK-dependent signaling are likely to influence the response
to therapeutic interventions.
In this study, we employed an informatics approach to identify novel
transcripts enriched in the bladder relative to other hollow organs.
This analysis revealed Sh3gl2/endophilin A1, a known regulator
of RTK endocytosis, to be highly expressed in normal urothelium,
and lost with high frequency in human UC specimens, including
in muscle-invasive disease. RNAi-mediated silencing of Sh3gl2 in
well-differentiated UC cells led to increased proliferation and colony
formation in vitro, increased phosphorylation of EGFR, Src family
kinases (SFKs), and STAT3, and promoted growth of xenografts




Sh3gl2 was identified as a transcript highly enriched in normal
bladder epithelium using bioinformatics analysis of publicly available
databases. Briefly, expression profiles were obtained from the Novartis
SymAtlas [11] (NCBIGEO accessionGSE1133) and theGenitourinary
Development Molecular Anatomy Project (GUDMAP) [12,13] (NCBI
GEO accession GSE11221). Both data sets were already normalized;
we further removed probe sets that were Affymetrix controls or were
never called present and log2-transformed the data. Between-tissue dif-
ferential expression analysis was performed by computing moderated
t-statistics [14] using the limma package [15] from Bioconductor [16].
We corrected for multiple hypothesis testing by using the false discov-
ery rate [17]. With the GUDMAP data set, we compared detrusor to
stroma and also detrusor to urothelium (two pairwise comparisons);
in SymAtlas, we compared bladder to each of intestine, heart, kidney,
liver, lung, prostate, stomach, trachea, and uterus (for a total of nine
pairwise comparisons). We identified genes with a false discovery rate
below 10% and fold change greater than 5 or less than −5 in every
comparison within each data set. The intersection of differentially
expressed genes between the two data sets (SymAtlas and GUDMAP)
was determined using Entrez Gene identifiers. All analyses were per-
formed in the statistical language R (http://www.r-project.org).
Sh3gl2 mRNA and Protein Expression in Human Subjects
Differential expression of Sh3gl2 mRNA levels in three indepen-
dent cohorts of human subjects with UC [18–20] was determined
using the Compendia Bioscience Oncomine bioinformatics platform
(www.oncomine.com; Compendia Bioscience, Ann Arbor, MI). The
reporters employed for microarray analysis were Affymetrix 205751_at
[18,19] and Illumina ILMN_1661491 [20]. Expression of Sh3gl2
protein was evaluated using commercially available bladder cancer
tissue microarrays from either Folio Biosciences (Columbus, OH) or
US Biomax, Inc (Rockville, MD). Specific immunohistochemical
(IHC) staining of Sh3gl2 in bladder tissue was verified using two inde-
pendent antibodies against Sh3gl2: rabbit anti-Sh3gl2 (12345-1-AP;
ProteinTech Group, Inc, Chicago, IL; not shown) or goat anti-Sh3gl2
(sc-10874; Santa Cruz Biotechnology, Santa Cruz, CA; Figure 1D,
b and d ). Specificity of staining was confirmed using preincubation
of antibody with peptide (Figure 1D, c). Following antibody valida-
tion, tissue microarrays were stained with goat anti-Sh3gl2 antibody
(1:50 dilution) using a standard immunoperoxidase approach [21].
Staining extent and intensity were scored independently by two in-
vestigators (E.M.G. and D.D.V.) and assigned values of 0, 1, 2, or
3 corresponding to absent, low, moderate, and high Sh3gl2 signal,
respectively. Chi-squared analysis of Sh3gl2 expression was performed
comparing benign and malignant specimens as well as between tumor
grades and stages. All statistical analyses were performed with SPSS
15.0 (Chicago, IL).
Cell Culture
A panel of bladder cancer cell lines was assembled for this study as
follows: RT4, T24, TCCSUP, and J82 cell lines were obtained from
ATCC (Manassas, VA); 253J-P, 253J-BV, and 253J-BVR were a gen-
erous gift from Dr I. Fidler (MD Anderson Cancer Center, Houston,
TX); MGH-U1, MGH-U3, and MGH-U4 were from Dr Chin-Lee
Wu (Massachusetts General Hospital, Boston,MA); 5637, UM-UC3,
andUM-UC9were kindly provided byDrMonica Liebert (University
of Michigan, Ann Arbor, MI); SW780 cells were from Dr David
Berman (Johns Hopkins University, Baltimore, MD); BOY cells were
fromDr Enokida of Japan. TRT-HU-1 cells were generated in the lab-
oratory of Dr Louis Liou and described by us recently [22]. Cells were
cultured in McCoy’s 5A medium (RT4, T24, MGH-U1, MGH-U3,
MGH-U4), Dulbecco’s modified Eagle’s medium (TCCSUP, J82,
UM-UC3, UM-UC9, 5637, TRT-HU1), minimal essential medium
(253J-P, 253J-BV, 253J-BVR, BOY), or RPMI 1640 supplemented
with heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin,
100 μg/ml streptomycin, and heat-inactivated FBS (Valley Biomedical,
Winchester, VA). The following cell lines have been authenticated by
DNA fingerprinting using short tandem repeat profiles: RT4, T24,
TCCSUP, J82, 5637, UM-UC3, and UM-UC9.
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Manipulation of Sh3gl2 Expression In Vitro
For stable knockdown, RT4 cells were infected with lentiviral parti-
cles encoding nontargeting shRNA or one of five independent shRNAs
targeting Sh3gl2 (MISSION shRNA; all from Sigma-Aldrich, St Louis,
MO). Forty-eight hours after transduction, cells were switched to me-
dium supplemented with 0.4 μg/ml puromycin to select stable trans-
ductants. Screening of stable populations by immunoblot analysis
identified sh184 and sh2103 as giving the greatest extent of silencing.
Subsequent analysis of single-cell clones led to selection of sh184 C3,
sh184 C9, sh2103 C8, and sh2103 C10 for initial biochemical and
phenotypic analysis. To restore Sh3gl2 expression in T24 or RT4 cells,
an entry clone expressing Sh3gl2 (pDONR201-Sh3gl2) was obtained
from the Dana Farber/Harvard Cancer Center Plasmid Resource core
and recombined into pLenti6/V5-DEST using LRClonase (Invitrogen,
Grand Island, NY). Recombinants were screened for expression in
human embryonic kidney 293 (HEK293) cells and selected for pack-
aging into viral particles using the ViraPower Lentivirus Expression
System (Invitrogen). Viral supernatants from 293FT cells transfected
with pLenti6/Sh3gl2 or with pLenti6/LacZ control vector were used
to infect T24 or RT4 cells, and stable populations were isolated follow-
ing incubation in blasticidin (6 μg/ml for T24 and 4 μg/ml for RT4).
Re-expression was verified by immunoblot analysis as outlined below.
Evaluation of Sh3gl2 mRNA and Protein Levels
Levels of Sh3gl2 mRNA in cell lines or tissues were assayed by semi-
quantitative real-time reverse transcription–polymerase chain reaction
Figure 1. Identification of Sh3gl2 as a transcript that is highly enriched in the bladder urothelium. (A) SymAtlas screenshot of microarray
hybridization analysis for Sh3gl2 in mouse organs illustrating high signal intensity in tissues from the nervous system, as well as the
bladder (circled in green). (B) Semiquantitative real-time RT-PCR analysis of selected mouse tissues verified enrichment of Sh3gl2 mRNA
in the nervous system tissue and bladder. Data are presented as expression level relative to that in heart (following normalization to
GAPDH), which is assigned a value of 1, and represent mean ± SD of triplicate values. (C) cDNAs prepared from urothelium, stroma, and
detrusor smooth muscle tissue microdissected from mouse bladders were analyzed for expression of Sh3gl2 as well as the urothelial
marker uroplakin 2 and the smooth muscle marker smooth muscle myosin heavy chain by semiquantitative real-time RT-PCR. As shown
in the left panel, Sh3gl2 was expressed predominantly in the urothelium, with minimal mRNA detectable in stroma or detrusor smooth
muscle. Effective separation of urothelial, stromal, and smooth muscle tissue by laser capture microdissection was demonstrated by
restricted expression of uroplakin 2 and smooth muscle myosin heavy chain to urothelial and smooth muscle tissues, respectively (right
panel). (D) IHC staining of mouse bladder tissue revealed Sh3gl2 expression to be restricted to the urothelium (b, d), with no signal
evident in submucosa or muscle. Preincubation of primary antibody with blocking peptide eliminated signal completely (c), confirming
antibody specificity. No background signal was detected in sections receiving secondary antibody only (a). Scale bar, 100 μm.
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(RT-PCR) using gene-specific primer assays (SA Biosciences, Frederick,
MD), essentially as described [23]. The relative abundance of a given
transcript was estimated using the 2−ΔΔCt method, following normaliza-
tion to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH ). Sh3gl2 protein levels were evaluated by immunoblot anal-
ysis as described [23]. Antibodies used were given as follows: rabbit anti-
Sh3gl2 (12345-1-AP; ProteinTech Group), goat anti-Sh3gl2 (sc-10874)
and rabbit anti-GAPDH (sc-25778; Santa Cruz Biotechnology), rabbit
anti-EGFR, rabbit anti–phospho-EGFR Y1068, rabbit anti–phospho-
EGFR Y1086, mouse anti–non-phospho-Src Y416, rabbit anti–phospho-
Src Y416, mouse anti-STAT3, and rabbit anti–phospho-STAT3 Y705
(all from Cell Signaling Technology, Danvers, MA).
Indirect Immunofluorescence
To assay localization of the EGFR in response to Sh3gl2 silencing,
cells were seeded on coverslips in 24-well plates at 30,000 cells/well.
Cells were serum-depleted in serum-free McCoy’s 5A medium for
24 hours before stimulation with EGF for 10 minutes at 37°C. Follow-
ing incubation, cells were fixed in 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 20 minutes on ice and permeabilized with
0.2% Triton X-100 in PBS for 10 minutes. Cells were washed four
times with 500 μl of PBS, and nonspecific binding sites were blocked
in PBS/1% normal donkey serum/5% BSA for 1 hour at room tem-
perature. Coverslips were rinsed once with PBS and incubated with
anti-EGFR rabbit monoclonal antibody (D38B1, #4267; Cell Signal-
ing Technology) or anti-EGFR mouse monoclonal antibody (R19/48
mix, #AHR5062; Life Technologies, Grand Island, NY), both at a
dilution of 1:200 in PBS/1% normal donkey serum/5% BSA over-
night at 4°C. Coverslips were washed four times with PBS for 5 min-
utes each wash before addition of Cy3-conjugated donkey anti-rabbit
or donkey anti-mouse secondary antibody (1:500) in PBS/1% normal
donkey serum for 1 hour at room temperature. Coverslips were
washed four times with PBS and then mounted in Vectamount (Vector
Laboratories, Inc, Burlingame, CA). Cells were visualized using an
Axioplan-2 microscope (Carl Zeiss MicroImaging, Inc, Thornwood,
NY). To quantify staining, cells were counted and scored qualitatively
on the basis of the extent of internalization of EGFR. Three different
parameters were assigned to describe localization of the EGFR. Cells
with more than 90% of EGFR staining on the membrane (Memb)
were counted as membrane bound. Cells with more than 90% cyto-
plasmic were counted as cytoplasmic (Cyto) and cells with both, i.e.,
less than 90% staining either on the membrane or in the cytoplasm
were considered as a mixture (Memb + Cyto). The numbers obtained
on the basis of the scoring method were then plotted as a percentage
of the total cells scored for each population.
Proliferation Assay
To determine effects of Sh3gl2 silencing on proliferation, cells were
seeded in 24-well plates at a density of 10,000 cells/well. Cell density
at selected time points was assessed by crystal violet assay, as described
[24], with absorbance at 570 nm determined using a microplate spectro-
photometer. In some experiments, the effect of lapatinib or saracatinib
on proliferation was assessed. In each case, absorbance at a given time
point was expressed as a percent of absorbance on day 0 to control for
variations in plating efficiency.
Clonal Growth Assay
Cells were seeded at a density of 500 cells/well in six-well tissue cul-
ture plates in complete medium. Medium was changed every 4 to
5 days during the assay. Fourteen days after plating, cells were fixed
in 1% glutaraldehyde and stained with crystal violet as outlined for
the proliferation assay. Plates were imaged using an Olympus SZX16
dissecting microscope with a DP71 high-resolution digital camera, and
the number and size of colonies were determined using ImageJ software
[National Institutes of Health (NIH), Bethesda, MD].
Phospho-kinase Proteome Array
To detect phosphorylation profiles of various intracellular signaling
proteins in the control versus Sh3gl2-silenced RT4 clones, we used the
Human Phospho-Kinase Array (Catalog No. ARY003; R&D Systems,
Minneapolis, MN). Cells (500,000) were seeded on 6-cm dishes and
allowed to grow for 48 hours. Cells were serum starved for 16 hours
followed by treatment with 10 nM EGF or vehicle for 10 minutes.
Cells were lysed and processed as per the manufacturer’s instructions.
Briefly, array membranes were incubated with 300 μg of protein lysates
followed by washing as instructed. Phosphorylation status of bound
proteins was subsequently detected by incubating the membranes with
biotinylated detection antibodies followed by application of streptavidin-
HRP and chemiluminescence detection reagents. Signals were visualized
following exposure of membranes to X-ray film. Spots were measured
using ImageJ software and calculated for the intensity of the average
signal of the pair of duplicated spots. Background signal was subtracted
from each of the spots.
Generation of Tissue Recombinant Xenografts In Vivo
To determine the significance of Sh3gl2 knockdown on tumor
growth in vivo, tissue recombination experiments were performed in
which control RT4 clones or clones silenced for Sh3gl2 were recom-
bined with embryonic rat bladder mesenchyme and implanted under
the renal capsule, essentially as described [25–27]. Briefly, pregnant rats
(Harlan Laboratories, Tampa, FL) were sacrificed at E16 (plug day = 0)
and urogenital sinusmesenchyme was isolated from embryonic bladders
manually under microscopic examination. To prepare recombinants,
control and Sh3gl2-silenced RT4 clones were resuspended in rat tail col-
lagen and setting solution, and aliquots were droplet-plated in 10-cm
dishes. Following the insertion of one embryonic bladder mesenchyme
per aliquot, tissue recombinants were placed at 37°C for 30 minutes to
promote solidification.McCoy’smodifiedmedium containing 10%FBS
was then applied to solidified grafts. The following day, tissue recombi-
nants were placed under the left kidney capsules of severe combined
immunodeficient mice. Grafts were maintained in vivo for 3 weeks
before euthanasia, tissue harvest, and determination of tumor burden.
All animal work was conducted in accordance with institutional animal
care guidelines. Tissue was subsequently embedded in optimal cutting
temperature (OCT) compound (Sakura) and stored at −80°C.
Statistical Analysis
Where appropriate, comparisons between experimental groups
were performed using Student’s t test. P values are indicated in fig-
ure legends or on figures where relevant, with P < .05 considered
statistically significant.
Results
Sh3gl2 (Endophilin A1) Is Highly Expressed in Normal
Urothelium and Decreased in Bladder Cancer
Previous studies have suggested restricted expression of Sh3gl2/
endophilin A1 to the brain and central nervous system [28]. However,
752 Sh3gl2 Loss Promotes Bladder Cancer Progression Majumdar et al. Neoplasia Vol. 15, No. 7, 2013
several recent reports have identified Sh3gl2 mRNA and protein
in cancers of the breast, head and neck, and ovary [29–31], indi-
cating a broader pattern of expression than initially believed. Using
an informatics-based analysis of expression profiles from normal tissues
to identify novel transcripts in visceral organs, we identified the urinary
bladder as a major site of expression of Sh3gl2 (Figure 1, A and B).
Sh3gl2 was one of only three transcripts identified as highly enriched
in our analysis of two independent publicly available data sets that used
different Affymetrix microarray types (see Materials and Methods
section), despite the known confounders arising from integration of
independent data sets and differing Affymetrix microarray types
[32,33]. As shown by laser capture microdissection coupled with
semiquantitative real-time RT-PCR (Figure 1C ) and IHC staining
with anti-Sh3gl2 antibody (Figure 1D), expression of Sh3gl2 is largely
Figure 2. Sh3gl2 loss in bladder cancer correlates with tumor progression. (A) Analysis of three independent cohorts of bladder cancer
specimens (i–iii) using the Oncomine database revealed decreased Sh3gl2 mRNA levels in both superficial and invasive lesions compared
to normal bladder tissue. (B) IHC analysis of a bladder cancer tissue microarray (TMA) revealed a marked decrease in Sh3gl2 expression
in cancer tissues versus noncancerous tissues, as well as a trend toward decreased expression in high-grade versus low-grade cancers.
Representative images of Sh3gl2 staining in low- and high-grade lesions are presented in a and b; c represents the control receiving no
primary antibody. Original magnification, ×200. (C) Representative staining of (a) benign, (b) low-grade, and (c) high-grade lesions on a blad-
der cancer progression TMA. Original magnification, ×200. (D) Quantification of IHC staining of a bladder cancer progression array revealed
frequent and progressive loss of Sh3gl2. Graphs show the proportion of tissue specimens (%) in each subgroup with low (−/+) versus high
(++/+++) intensity staining for Sh3gl2 protein. Sh3gl2 staining intensity was significantly lower in (i) malignant versus benign specimens
(P < .001), (ii) in high-grade (G3) versus low-grade (G1/G2) specimens (P < .001), and (iii) in muscle-invasive versus non–muscle-invasive
specimens (P = .03), as well as non–muscle-invasive versus benign specimens (P < .001).
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restricted to the murine urothelium (Figure 1D, b and d ). Notably,
Sh3gl2 is expressed on human chromosome 9, a frequent site of ge-
nomic alterations in development of bladder cancer [34–36]. How-
ever, the association between Sh3gl2 and UC development and/or
progression has not been investigated.
Interrogation of the Oncomine human tumor profiling database
revealed a statistically significant decrease in Sh3gl2 mRNA levels in
both superficial and invasive UC compared to normal bladder tissue
in three independent studies [P < .05; Figure 2A, (i)–(iii)] [18–20].
In the study by Lee et al. [Figure 2A, (iii)], Sh3gl2 was in the top third
percentile of downregulated genes. To determine whether Sh3gl2
protein was also altered in UC, we stained a human tissue microarray
comprising 80 normal and cancerous specimens of bladder tissue with
a validated antibody to Sh3gl2 (see Figure 1D). In agreement with
data from the mouse, Sh3gl2 expression was predominantly epithelial
(Figure 2B). Sh3gl2 protein levels were decreased in UC compared to
noncancerous tissue, with only 19% of UC specimens versus 63% of
benign tissue showing high expression of the antigen (P = .001;
Figure 2B). To further determine whether loss of Sh3gl2 was associated
with disease progression, we stained a bladder cancer progression array
comprising 202 cases, of which 169 gave meaningful data (Table 1 and
Figures 2C and W1). As shown in Figure 2D, (i), Sh3gl2 levels were
low or absent at significantly higher frequency in malignant samples
compared with benign samples (P < .001). Sh3gl2 levels decreased pro-
gressively with increasing tumor grade (Figure 2D, (ii), P < .001), with
the majority of high-grade specimens showing little or no expression
(G3 vs G1/G2, P = .001). Furthermore, Sh3gl2 expression was sig-
nificantly lower in muscle-invasive compared to non–muscle-invasive
bladder cancer specimens (Figure 2D, (iii), P = .03). Expression of
Sh3gl2 in non–muscle-invasive specimens was also significantly lower
compared to benign tissues (Figure 2C , (iii), P = .001). From these
analyses, it appears that the loss of Sh3gl2 expression is a frequent
and progressive event in UC pathogenesis. Differential expression of
Sh3gl2 in muscle-invasive versus non–muscle-invasive specimens sug-
gests that Sh3gl2 status in tumors may have prognostic implications.
Silencing of Sh3gl2 Expression Enhances Proliferation
To facilitate mechanistic analysis of the role of Sh3gl2 in UC, we
profiled 20 different UC cell lines representing different degrees of
aggressiveness. Notably, we observed a striking absence of Sh3gl2
mRNA and protein expression in 19 of 20 cell lines, with significant
expression detected only in the low-grade, well-differentiated cell line
RT4 (Figure 3, A and B). To investigate the functional significance
of Sh3gl2 loss in UC, we employed lentivirus-encoded shRNAs to
downregulate its expression in RT4 cells. Among five independent
shRNA constructs, sh184 and sh2103, which bound to seed sequences
in the coding and 3′ untranslated regions of the Sh3gl2 transcript,
respectively, produced >75% knockdown at the protein level in RT4
populations. Independent single-cell clones sh184 C3, sh184 C9,
sh2103 C8, and sh2103 C10, along with shCtrl C2 were selected for
subsequent analyses (Figure 3C ). Stable silencing of Sh3gl2 led to
increased proliferation of all four clones relative to control cells in
which Sh3gl2 was intact (Figure 3D). Sh3gl2 silencing also promoted
increased survival and colony formation in cells seeded at clonal density,
as determined by colony number (Figure 3E ) and colony area (Fig-
ure 3F ). The extent of colony area appeared to correlate with the extent
of Sh3gl2 knockdown, with greater average colony area in sh2103
clones compared to sh184 clones. To determine whether Sh3gl2 loss
altered growth in vivo, we grafted recombinants comprising RT4 stably
silenced with control or Sh3gl2-targeted shRNA together with rat fetal
bladder mesenchyme under the renal capsule of athymic mice. As
shown in Figure 3H , two of three RT4 clones lacking Sh3gl2 showed
increased tumor burden compared to nontargeted controls, with a
comparable increase in xenograft size observed in two independent
clones targeted with sh2103. Together, these findings suggest that
Sh3gl2 normally regulates survival and growth-promoting signals in
urothelial cells.
Sh3gl2 Silencing Enhances EGFR-Mediated Signaling
Sh3gl2 is known to regulate signal transduction with RTKs, such as
the EGFR/ErbB1 and c-Met/HGF-R, through its ability to control
endocytosis [37,38]. In agreement with this activity, stable silencing
of Sh3gl2 attenuated EGF-induced EGFR internalization compared
to that observed in cells with intact Sh3gl2 expression. Specifically,
RT4 cells lacking Sh3gl2 retained EGFR on the plasma membrane
to a greater extent than control RT4 cells in which Sh3gl2 was intact
(Figure 4, A and B). Similar results were obtained with two indepen-
dent anti-EGFR antibodies. Moreover, Sh3gl2 silencing consistently
enhanced phosphorylation of the EGFR at multiple activating residues
(Figures 4C and W2). In agreement with EGF-dependent signal-
ing in other tumor types, HER2 was also phosphorylated in RT4 cells
exposed to EGF (data not shown), suggesting that a proportion
of the activated EGFR exists in a heterodimer with HER2. Sh3gl2
knockdown also decreased sensitivity to the dual specificity EGFR/
HER2 inhibitor, lapatinib (Figure 4D). In the presence of vehicle
(DMSO), growth of sh184 C9 and sh2103 C8 clones was increased
relative to shCtrl C2 (P < .001), in a manner consistent with the ex-
tent of knockdown, with sh2103 C8 showing higher proliferation
than sh184 C9. A similar pattern was observed in the presence of
lapatinib, with both sh184 C9 and sh2103 C8 reaching higher den-
sities than shCtrl C2 (P < .001). Notably, sh2103 C8 cells were es-
sentially insensitive to the inhibitory effects of lapatinib (P = .654,
sh2103 C8 DMSO vs sh2103 C8 lapatinib).
Sh3gl2 Silencing Increases Signaling through Src and STAT3
To explore signaling pathways activated downstream of Sh3gl2 si-
lencing, whole-cell lysates from vehicle or EGF-treated cells were probed
using a phospho-kinase array comprising 46 target phosphoproteins.
From this analysis, we identified cohorts of phosphoproteins upregu-
lated by Sh3gl2 knockdown under both basal and EGF-stimulated
Table 1. Summary Data for Tissue Specimens on Progression Array.
Benign Malignant
Gender
M n = 38 (88.4%) n = 102 (81.0%)
F n = 5 (11.6%) n = 24 (19.0%)
Age 54.5 years (17–73 years) 60.7 years (25–85 years)
Grade
1 N/A n = 33 (26.2%)
2 N/A n = 58 (46.0%)
3 N/A n = 35 (27.8%)
Stage
T1 N/A n = 65 (38.5%)
T2 N/A n = 38 (22.5%)
T3 N/A n = 20 (11.8%)
T4 N/A n = 3 (1.8%)
Pathology Inflammation, n = 24 (55.8%) UC, n = 125 (99.2%)
Hyperplasia, n = 11 (25.6%) Undifferentiated carcinoma, n = 1 (0.8%)
Normal, n = 6 (14.0%)
Pheochromocytoma, n = 2 (5.7%)
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Figure 3. Sh3gl2 is lost with high frequency in bladder cancer cell lines and regulates cell growth in vitro and in vivo. Sh3gl2 mRNA (A)
and protein (B) levels were analyzed in a panel of 20 bladder epithelial cell lines by semiquantitative real-time RT-PCR or immunoblot analy-
sis, respectively; data from 14 cell lines are presented. Only the low-grade papilloma-derived cell line RT4 expressed detectable levels of
Sh3gl2. (C) RT4 cells infected with lentivirus encoding shRNAs directed against five distinct regions of the Sh3gl2 transcript (sh184, sh646,
sh989, sh1430, and sh2103) or with nontargeting control shRNA (shCtrl) were analyzed for Sh3gl2 expression by immunoblot analysis
with two independent anti-Sh3gl2 antibodies and identified sh184 and sh2103 as yielding efficient knockdown of Sh3gl2 (left panel).
Single-cell clones isolated from shCtrl (C2), sh184 (C3 and C9), and sh2103 (C8 and C10) were selected as candidate clones for functional
analysis (right panel). (D) Proliferation of Sh3gl2-silenced cells, as determined in a biomass assay, was increased in all four clones com-
pared to RT4 control cells at all time points tested (P < .05). Data are representative of at least three independent experiments. Control
and Sh3gl2-targeted clones seeded at clonal density were evaluated for (E) colony number and (F) colony area 14 days after seeding. Loss
of Sh3gl2 significantly increased cell survival (number) in three of four clones (*P < .01) and proliferation (area) in all four Sh3gl2-silenced
clones compared to controls (*P< .01). (G) Representative images of clonal growth assays for four Sh3gl2-silenced clones and the control
clone. (H) Tissue recombinants comprising RT4 cells stably silenced with control or Sh3gl2-targeted shRNA combined with rat fetal bladder
mesenchyme were implanted under the renal capsule of severe combined immunodeficient mice and harvested 3 weeks after implanta-
tion. Representative images indicating grafts in situ are indicated. The graph indicates wet weight of grafts generated from three to four
grafts per indicated clone and data are presented as means ± SD.
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conditions. Increased phosphorylation of Akt (T308) and glycogen
synthase kinase 3α/β (GSK3α/β), p27 (T198), and STAT4 was evi-
dent in Sh3gl2-silenced cells in the absence of growth factor treatment
(Figure 5A). In EGF-treated cells, we observed increased phosphoryla-
tion of p27, Pyk2, PLCγ-1, Paxillin, c-Jun, STAT-2, -3, -5, and -6, as
well as the SFKs Fgr, Fyn, Yes, Hck, and Lck (Figure 5B). Since SFKs
and STAT3 have been implicated in oncogenic signaling and are known
to signal within the same pathway, we proceeded to validate these tar-
gets by immunoblot analysis. As illustrated in Figure 5C , we observed
increased levels of phospho-Src Y416, a site conserved in multiple
SFKs, in Sh3gl2-silenced cells compared to control cells under both basal
and EGF-stimulated conditions. In addition, increased phosphorylation
of STAT3 Y705 was also observed in Sh3gl2-silenced cells compared
to controls. To explore the functional significance of increased phos-
phorylation of SFKs with Sh3gl2 knockdown, we performed growth
assays in the presence of the Src inhibitor saracatinib. As observed pre-
viously, cells silenced for Sh3gl2 reached higher densities than control
cells with intact Sh3gl2 in the absence of inhibitor; however, growth
of both control and Sh3gl2-silenced cells was inhibited significantly in
the presence of saracatinib (P < .05; Figure 5D).
Re-expression of Sh3gl2 Attenuates Growth and Migration
To obtain additional evidence to support a role for Sh3gl2 in regulat-
ing oncogenic behaviors, we also assessed the consequence of restoring
Figure 4. Stable Sh3gl2 silencing attenuates EGFR internalization and enhances receptor activation. (A) Control and Sh3gl2-silenced RT4
cells were seeded on coverslips, serum-depleted for 24 hours, and treated without or with 10 nM EGF for 10 minutes at 37°C. Localization
of the EGFRwas visualized by indirect immunofluorescence staining. Nuclei are counterstainedwith 4′, 6-diamidino-2-phenylindole (DAPI).
Data are representative of three independent trials. Originalmagnification, ×63. (B) The extent of EGFR internalization under the conditions
indicated in A was quantified and plotted as the percentage of cells showing EGFR that was localized predominantly on the membrane
(Memb), predominantly in the cytoplasm (Cyto), or present both in the cytoplasm and on themembrane (Cyto +Memb). (C) Serum-depleted
control and Sh3gl2-silenced RT4 cells were treated with 10 nM EGF for 10 minutes at 37°C, and whole-cell lysates were prepared for eval-
uation of receptor phosphorylation. IncreasedEGFRphosphorylationwas evident in all four clones inwhich Sh3gl2was silenced compared
to nontargeted control cells. Data are representative of at least four independent experiments. (D) Control and Sh3gl2-silenced RT4 cells
were treatedwith vehicle (DMSO) or 0.3 μM lapatinib for 5 days and cell number determined by biomass assay. Data represent absorbance
on day 5 expressed as a percentage of absorbance on day 0 and are the means ± SD of four values. *, shCtrl C2 DMSO versus sh184 C9
DMSO or sh2103 C8 DMSO; **, shCtrl C2 lapatinib versus sh184 C9 lapatinib or sh2103 C8 lapatinib. Data are representative of at least
two independent experiments.
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Figure 5. Stable Sh3gl2 silencing increases phosphorylation of SFKs and STAT3. Lysates of control and Sh3gl2-silenced cells treated with-
out (A) or with (B) 10 nM EGF for 10 minutes were analyzed using a phospho-kinase proteome array. Graphs and tables indicate phospho-
proteins that were altered by >1.5-fold in response to Sh3gl2 silencing. Representative images of phospho-array blots from each condition
are shown. (C) Independent lysates immunoblotted with the indicated antibodies revealed enhanced phosphorylation of SFKs at Y416
(or corresponding conserved residue) and STAT3 at Y705. (D) Control and Sh3gl2-silenced RT4 cells were treated with vehicle (DMSO)
or 0.125 μM saracatinib for 5 days and cell number determined by biomass assay. Graphs illustrate absorbance on day 5 expressed as
a percentage of absorbance on day 0, and data are the means ± SD of two values for DMSO and six values for saracatinib. Data are
representative of at least two independent trials. *P < .05 compared to DMSO-treated condition.
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its expression in RT4 clones silenced for Sh3gl2 and in T24 cells.
Rescue of Sh3gl2 expression in the RT4 background (Figure 6A)
attenuated proliferation of two independent clones, 2103C8 and
2103C10, when seeded at high density (Figure 6, B and C ) and at
clonal density (data not shown). In addition, forced expression of
Sh3gl2 in T24 cells (Figure 6D) attenuated proliferation to a modest
but statistically significant extent (Figure 6E ) compared to cells ex-
pressing an irrelevant gene, LacZ. In addition, Sh3gl2 restoration
inhibited EGF-induced migration in a wound healing assay by greater
than 50% (Figure 6, E and F ; *P < .05).
Discussion
In this study, we describe a novel role for Sh3gl2 in regulation of
urothelial cancer pathogenesis and progression. The evidence support-
ing our conclusions is given as follows: 1) Analysis of human tumors
revealed frequent and progressive loss of Sh3gl2 mRNA and protein, as
well as significantly enhanced loss of expression in muscle-invasive
lesions; 2) evaluation of 20 UC cell lines revealed only one, RT4,
which expressed detectable Sh3gl2 mRNA and protein; 3) RNAi-
mediated silencing of Sh3gl2 in RT4 cells enhanced proliferation
and colony formation, activation of ErbB receptors, SFKs and STAT3,
and growth of UC xenografts in vivo; 4) reconstitution of Sh3gl2
expression in RT4 cells and T24 cells attenuated proliferation and
migration, respectively. Together, these findings provide the first evi-
dence linking alterations in Sh3gl2 to oncogenic activity in bladder
cancer and implicate Sh3gl2 as an important inhibitor of tumor pro-
gression that restrains activation of kinases such as the EGFR and Src
family members.
Sh3gl2 was identified initially through functional screening as an
SH3 domain–containing protein [39] and, based on Northern blot
analysis of a panel of human tissues, was found to be preferentially
expressed in the brain [28]. In that study, however, bladder tissue
was not analyzed. On the basis of both microarray hybridization data
deposited in SymAtlas, as well as quantitative PCR validation by us,
the level of Sh3gl2 mRNA in mouse bladder was comparable to that
detected in the brain and spinal cord. Further analysis of microdissected
bladder tissue confirmed restriction of Sh3gl2 mRNA and protein to
the urothelial compartment. Interestingly, Sh3gl2 is expressed on hu-
man chromosome 9p (9p22), a genomic region associated with genetic
and epigenetic alterations that lead to gene silencing and bladder tumor
development [40]. Chromosome 9p alterations occur early in develop-
ment of a number of tumor types and the biologic consequences of
Figure 6. Restoration of Sh3gl2 expression inhibits proliferation and migration. (A) Rescue of Sh3gl2 expression in RT4 cells using Sh3gl2-
expressing lentivirus was verified by immunoblot analysis. (B, C) Re-expression attenuated proliferation in two independent clones silenced
for Sh3gl2, compared to cells expressing an irrelevant gene, LacZ. *P < .05 compared to LacZ at corresponding time point. (D) Recon-
stitution of Sh3gl2 expression in T24 cells was confirmed by immunoblot analysis. (E) Restoration of Sh3gl2 expression inhibited pro-
liferation, as measured at 48 hours after seeding. *P < .05 compared to proliferation in LacZ-expressing cells. (F) Restoration of Sh3gl2
expression inhibited EGF-stimulated migration in T24 cells. (G) The graph represents average distance migrated, and data are presented
as means ± SD. *P < .05 compared to distance migrated in LacZ-expressing cells.
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such changes have typically been ascribed to inactivation of CDKN2A,
which encodes p16 (reviewed in [41]). However, several reports on a
range of cancers describing chromosome 9p deletions distal to the
CDKN2A locus [42–45] have suggested the existence of additional
genes that may be targeted by genomic rearrangements. Consistent
with this possibility, analyses in head and neck carcinoma as well as
breast and non–small cell lung cancers have implicated Sh3gl2 as a
candidate tumor suppressor gene in this region [29,30,46]. Further-
more, studies in breast as well as head and neck tumors have demon-
strated hypermethylation of the Sh3gl2 promoter and suggested this
as a potential mechanism of Sh3gl2 silencing [29,30]. In agreement
with these findings, we found a CpG island in the Sh3gl2 proximal
promoter to be hypermethylated in T24 cells that lack Sh3gl2 expres-
sion, in contrast to RT4 cells in which the Sh3gl2 promoter CpG
site was completely unmethylated, as assessed by methylation-sensitive
restriction analysis and PCR of genomic DNA (E.M.G. and R.M.A.,
unpublished observations). Thus, the absence of Sh3gl2 expression in
UC tumor cells may result, at least in part, from methylation-induced
gene silencing.
The biologic consequences of Sh3gl2 down-regulation are only just
beginning to be delineated. Stable silencing of Sh3gl2 in the RT4 cell
line, consistent with the down-regulation of Sh3gl2 mRNA and pro-
tein evident in urothelial cancer specimens, led to marked increases in
cell proliferation in vitro and xenograft growth in vivo. These findings
are in agreement with a recent report by Dasgupta and colleagues, in
which the Sh3gl2 gene was shown by single nucleotide polymorphism
(SNP) array analysis to be deleted frequently in non–small cell lung
cancer. In that study, forced expression of Sh3gl2 in cell lines lacking
endogenous expression attenuated oncogenic behaviors, including pro-
liferation and colony formation [46]. In agreement with the known
function of Sh3gl2 in regulating RTK endocytosis [37,38], we observed
retention of the EGFR/ERBB1 on the plasma membrane in response to
EGF stimulation following Sh3gl2 silencing in RT4 cells. In addition,
ligand-stimulated EGFR phosphorylation at several activating residues
was enhanced in Sh3gl2-silenced cells, consistent with reduced signal
attenuation that typically occurs by receptor internalization. An im-
portant finding in our study was the demonstration of increased
EGF-stimulated phosphorylation of multiple SFKs and STAT3 in cells
lacking Sh3gl2, both of which have been implicated in urothelial cancer
pathogenesis [47,48]. Sh3gl2-silenced cells were sensitive to saracatinib,
an SFK inhibitor currently undergoing evaluation in phase II clinical
trials for osteosarcoma and breast and pancreatic cancers [49]. Interest-
ingly, our data suggested that Sh3gl2 silencing also decreased sensitivity
to the growth-inhibitory effects of the EGFR/HER2 inhibitor lapatinib.
Decreased Sh3gl2-mediated internalization of EGFR in invasive andmeta-
static disease may explain why EGFR-targeted therapies in UC patients
have shown little or no activity in clinical studies [8]. Interestingly, a
recent study by Osterberg and colleagues demonstrated that genomic
loss of Sh3gl2 or CIN85, another component of the endocytosis appa-
ratus, correlated with resistance to chemotherapy in ovarian carcinoma
[31]. Notably, in that study, losses in either the Sh3gl2 or CIN85 locus
were evident in 70% of resistant tumors suggesting that impaired re-
ceptor endocytosis is an important contributor to drug resistance in
tumors. Thus, evaluation of Sh3gl2 status in urothelial, and possibly
other tumors, may inform our understanding of which targeted therapies
may be effective and the extent to which tumors are likely to respond to
a given therapeutic intervention.
Loss of Sh3gl2 appears to be a frequent alteration in development of
urothelial cancer, with levels continuing to decline with progression,
as evidenced by the significant decrease in protein expression between
non–muscle-invasive and muscle-invasive lesions. This observation
supports both chromosomal deletions and methylation as contributors
to significantly decreased Sh3gl2 expression in UC. Interestingly, forced
expression of Sh3gl2 expression in tumor cells lacking endogenous ex-
pression attenuated invasion [46] and migration (E.M.G. and R.M.A.,
unpublished observations), behaviors required for cells to metastasize.
Therefore, Sh3gl2 expression level, in conjunction with additional fea-
tures of tumor cells, may serve as a potential marker of risk for urothelial
tumor progression or recurrence and may enable determination of which
patients require more aggressive intervention in the form of surgery or
chemotherapy to improve prognosis. Investigation of Sh3gl2 expression
with respect to clinical outcomes is currently under consideration.
In summary, we present the first evidence linking Sh3gl2 to urothe-
lial cancer development and progression. Loss of Sh3gl2 is associated
with aggressive disease and promotes oncogenic activities including
up-regulation of ERBB receptors, SFKs and STAT3, and increased cell
survival and proliferation. These findings provide a platform for fur-
ther exploration of Sh3gl2-mediated regulation of kinase-dependent
signaling in vitro and in vivo and for evaluation of the prognostic utility
of Sh3gl2 status in patients with bladder cancer.
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Figure W1. The figure shows additional images from the bladder cancer progression tissue microarray stained for Sh3gl2. Consistent
with findings in Figure 2, Sh3gl2 levels decrease with progression from (A) benign to (B) low-grade to (C) high-grade lesions. Original
magnification, ×200.
Figure W2. The figure shows independent evaluation of total EGFR
levels in Sh3gl2-silenced RT4 clones and control RT4 cells treated
with EGF, using a different anti-EGFR antibody from that used to
generate data in Figure 4. Although signal avidity is lower following
EGF treatment, consistent with modification of antibody epitopes
following EGFR cytoplasmic domain phosphorylation, total EGFR
is evident in all four Sh3gl2-silenced RT4 clones and control RT4
cells in the absence or presence of EGF treatment. On the basis
of these findings, we conclude that Sh3gl2 silencing in RT4 cells
leads to enhanced phosphorylation of the EGFR.
